Main description:

The successful series of International Meetings on "Current Therapy in Nephrology" (now known around the world as "Sorrento Meeting") has continued this year with the third meeting of the series, updating on new therapeutic strategies in Nephrology. This time the meeting was held at the Cocumella Hotel of Sorrento, Italy, on May 27-30, 1990, in a wonderful atmosphere, with the participation of outstanding scientists, such as Drs. H. Auchincloss (Boston, USA), E. Bartoli (Udine, Italy), V. Bonomini (Bologna, Italy), M. Broyer (Paris, France), V. Cambi (Parma, Italy), G. Camussi (Naples, Italy), J.M. Dubemard (Lyon, France), G. Haycock (London, U.K.), G. Jacobs (Paris, France), C. Kjellstrand (Minneapolis, USA), R. Maiorca (Brescia, Italy), G. Maschio (Verona, Italy). As many as five hundred nephrologists from all over the world (European Countries, Israel, U.S.A., Taiwan, Corea, Japan) attended the meeting, actively participating in the discussion of a great number of good papers and posters.
Important lectures by invited speakers have dealed with mediators of inflammation, cellular immunity in glomerular pathology, immunosuppressive therapy in autoimmune nephropathies, treatment of hypertension in chronic renal failure, dialysis compatibility, xenogenic transplantation. Very interesting controversies have been included in the programme: "Extracorporeal or peritoneal dialysis for uremic children?" (M. Broyer against G. Haycock) and "Extracorporeal or peritoneal dialysis for diabetic uremic patients?" (c. Kjellstrand against C. Jacobs). Their presentation has been quite successful with a great participation in the discussion by Congress members.

Contents:

I. Glomerulonephritis.- Modulation of endothelial barrier and coagulant properties by hypoxia.- Cellular immunity in glomerular pathology primarily induced by immune-complexes.- Immunosuppressive treatment of autoimmune nephropathies.- Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome.- Treatment of nephrotic hyperlipidemia.- Effect of PSK administration followed by initial prednisolone therapy in the steroid responsive idiopathic nephrotic children.- Zinc therapy for minimal change nephrotic syndrome and its effect on IgG synthesis.- The nephrotic syndrome in the elderly: epidemiological data.- Antiaggregating platelet therapy in chronic glomerulonephritis (GN).- Membranoproliferative glomerulonephritis type I: a correlation between treated (138) and untreated (108) patients.- Methylprednisolone (MP) pulse therapy in childhood IgA nephropathy.- Immunosuppressive treatment of Berger's disease.- High dose intravenous human IgG in the treatment of idiopathic membranous nephropathy: preliminary report of a multicentric trial.- Treatment of patients with membranous nephropathy (MN).- Anticoagulant therapy and steroid pulse therapy to rapidly progressive IgA nephropathy.- Contemporary treatment of idiopathic membranous glomerulonephritis.- Effect of methylprednisolone pulse therapy in patients with Lupus Nephritis assessed by WHO morphologic classification.- Effect of Dilazep dihydrochloride (DZ) therapy in patients with chronic glomerulonephritis.- Follow-up of treated patients with primitive membranous nephritis.- Role of ACE inhibition in IgA nephropathy.- Early indicators of renal disease in parenteral substance abusers.- Platelet derived growth factor and interleukin-1 expression are increased in murine IgA nephropathy.- Effect of cyclosporine A on the anionic sites in the glomerular basement membrane of Puromycin nephrotic rats.- Therapeutic approach for the deteriorated renal function in IgA nephropathy.- IgA nephropathy and cytomegalovirus.- Intestinal permeability and antibodies against dietary antigens in IgA nephropathy.- Parameters affecting the poor prognosis of IgA nephropathy -a clinical study.- Successful induction of seroconversion and diminished proteinuria in 3 cases of hepatitis B virus (HBV) associated glomerulonephritis.- Goodpasture's syndrome: a clinical case.- Effects of Piretanide on renal function and the ANP/RAA-system in patients with the nephrotic syndrome.- Inhibition of the hydroxyl radical by dimethylthiourea and proteinuria in adriamycin experimental nephrosis.- Late treatment with Captopril worsens the course of Adriamycin nephropathy in rats.- II. Acute Renal Failure.- Acute renal failure after poisoning with concentrated acetic acid.- Daily recycled bicarbonate dialysis in treatment for acute renal failure in critically ill patients.- Endotoxin stimulates synthesis of platelet activating factor via production of tumor necrosis factor by human mesangial cells.- Reversible acute renal failure in Lupus Nephritis due to a hypertensive crisis.- Early effects of acute obstruction of biliary duct in the rat.- III. Chronic Renal Failure.- Treatment of hypertension in chronic renal failure. p.- Geographical distribution of the unknown aetiology end-stage renal failure in Greece.- Valuation of the immunological parameters in chronic renal insufficient patients with or without haemodialytic treatment.- Chronic renal failure (CRF) and lipidemic parameters.- The effect of cimetidine on parathyroid in the uremic patients.- Bone GLA protein in chronic renal failure.- Cystic diseases in uremia and HLA system.- Cardiac morphology evaluation in patients with chronic renal failure: an echocardiographic study.- ANP in chronic renal failure is related to plasma creatinine but not to blood pressure or dialysis.- Correlation of biochemical and histological indices of renal osteodystrophy in patients with mild to moderate chronic renal failure.- Does Indomethacin in Bartter's syndrome interfere with the membrane receptors for GH.- IV. Diabetic Nephropathy.- Advanced glycosylation end products: interactions with cells.- Antihypertensive treatment and evolution of incipient nephropathy in type II diabetic patients. A 30 month follow up.- Beneficial effect of dipyridamole on proteinuria in diabetic nephropathy.- Renal functional reserve (RFR) in patients with short term type I diabetes mellitus (DM1) without nephropathy.- Diabetic nephropathy: prevalence and risk factors.- The terminal complement complex (TCC) in the plasma of patients with type I diabetes mellitus. Relationship with albumin excretion rate.- Microalbuminuria and renal lesions in diabetic nephropathy.- Effect of dietary protein restriction on the progression of renal damage in diabetic nephropathy.- Diabetic nephropathy in outpatients with type 2 (non insulin-dependent) diabetes.- Prevalence of diabetic nephropathy in a single region: changes in acceptance rates in the last 8 years..- Arterial hypertension (AH) and microalbuminuria (MA) in patients with type 2 diabetes mellitus.- "Incipient" nephropathy, serum apolipoproteins and blood pressure levels in type 1 diabetes.- ACE inhibitors of diabetic nephrosis.- Radioisotopical studies of the glomerular filtrate in a group of insulin-dependent diabetics.- Diabetic nephropathy in type 2 (non insulin-dependent) diabetes: a cross-sectional study.- V. Hypertension.- Nifedipine versus Captopril in the treatment of severe hypertension of diabetic patients.- Effects of rHuEPO on the aldosterone secretion -an in vivo and in vitro study.- Efficacy and tolerability of Cilazapril (CLZ) in hypertensive patients (PTS) with chronic renal failure (CRF).- Long term results of renal angioplasty in patients with renovascular hypertension.- Nitrendipine in patients with end-stage renal disease and hypertension.- First choice treatment of dialysis-resistant hypertension: a crossover comparison of single oral dose of Captopril and Nifedipine.- Clinical study of Bunazosin treatment for patients with renal hypertension.- Vasodilatory prostaglandins and loop diuretics.- Systemic hypertension in 5/6 nephrectomized rats does not affect the changes caused by Low protein intake.- Diltiazem: its antihypertensive activity without renal effects in man.- Effects of Piretanide on sodium and potassium excretion and on renal hemodynamics.- VI. Dialysis.- How to improve biocompatibility in dialysis.- Captopril treatment of hypertensive patients on maintenance hemodialysis.- Importance of volume factors in dialysis-related hypertension.- Effects of different hemodialysis (HD) methods on the nutritional status of HD patients (pts).- Urea kinetic parameters in haemodialysis patients treated with erythropoietin.- Continuous ambulatory peritoneal dialysis as an alternative therapy to metal removal with Desferrioxamine B.- Endogenous hyperphosphatemia in patients treated with maintenance hemodialysis.- Prostacyclin in haemodialysis.- Atrial natriuretic factor, B-endorphin, parathyroid hormon and recombinant human erythropoietin in haemodialysis patients.- Altered membrane transport of choline in renal failure: a comparison of non-dialysed and haemodialysed patients.- Direct inhibitory effect of intravenous Calcitriol on parathyroid function in hemodialysis patients.- Maxillary "Giant Cell Brown Tumor" (GCBT) in a patient on maintenance hemodialysis (HD) with secondary hyperparathyroidism (SHPT): case report.- Prevention of thrombosis of vascular prosthesis in hemodialysis: effect of long-term treatment with urokinase at the end of the dialytic session.- Free erythrocyte protoporphyrin in hemodialysis patients treated with human recombinant erythropoietin.- The value of Desferrioxamine (DFO) test in accidental acute Aluminum overload in hemodialysis. Six months later, the influence of DFO treatment.- Comparative efficacy of two different intravenous dosages of recombinant human erythropoietin (rHuEPO) in the anemia of haemodialysis. Effects on iron stores.- Dialysis and urine flow.- Bone metabolism parameters in patients undergoing intravenous Calcitriol treatment.- Effect of Deferoxamine on Aluminum kinetics during hemodialysis.- Is zero net peritoneal ultrafiltration (Net UF) a desirable aim in CAPD.- Could secondary hyperparathyroidism influence the response to hepatitis B vaccination of hemodialyzed patients.- Recombinant human erythropoietin R-HuEPO, effective treatment in correction the anemia of patients in hemodialysis (HD).- Anti-HCV in HD: a preliminar report.- Effects of hemodialysis on cerebral blood velocity in uremic patients.- Acetate free biofiltration (A.F.B.): 12 months of experience.- Calcium carbonate (CaCO3) as a phosphate binder in patients on renal replacement therapy.- Classical and Alternative pathway complement activity in hemodialysis and CAPD patients.- Thrombotic risk during r-EPO therapy in hemodialized patients. A new hypothesys.- Improvement of treatment compatibility in dialysis by blood volume controlled ultrafiltration.- Continuous control of blood volume changes during hemodialysis and its implication for the determination of an optimal ultrafiltration-rate.- Computer modulated profile haemodialysis (CMP-HD) and vasoactive hormones.- Improvement of paired filtration dialysis (PFD) for optimum removal of small and large molecules.- Paired filtration dialysis (PFD). Spanish multicentric study.- Comparison of effects of erythropoietin (r-HuEPO) in patients on hemodiafiltration (HDF) vs conventional hemodialysis (SD).- Continuous ultrasonic measurement of whole blood protein concentration for the assessment of relative blood volume changes during hemodialysis.- Computer-modulated profile hemodialysis (CMP-HD) versus standard bicarbonate hemodialysis (BIC-HD).- New strategies enhance the role of peritoneal dialysis in renal replacement therapy.- Steady-state blood and tissue plasticizer concentration: in vivo comparison between DOP (DEHP) and TOT (TEHT).- Paired filtration dialysis (PFD): biocompatibility and depurative efficiency.- Myoglobin (MYO) removal by highly permeable polymethylmetacrylate (PMMA) in rhabdomyolysis -induced acute renal failure (RH-ARF).- Bicarbonate and calcium kinetics during paired filtration dialysis (PFD).- VII. Renal Replacement Therapy in Children.- Continuous ambulatory peritoneal dialysis (CAPD): The treatment of choice in paediatric chronic renal failure (CRF).- CAPD is not the best treatment for children with ESRD: a retrospective study of 23 patients who received both CAPD and hemodialysis.- Risk-orientated preparation of uremic children for renal transplantation.- Growth in children on long-term dialysis.- Carnitine (C) metabolism in renal insufficient and regular hemodialyzed children.- VIII. Renal Replacement Therapy in Diabetic Patients.- What dialysis is best for diabetic patients-hemodialysis or CAPD.- Peritoneal versus extra-corporeal dialysis for diabetic uremic patients: where do we stand in the early nineties.- Renal replacement therapy in diabetic patients.- The treatment of uremic diabetic patients (UDP) in Piemonte (dialysis and transplantation registry - RPDT): survival analysis.- Diabetes and renal replacement therapy in Italy: mode of treatment and major complications.- Renal transplantation (RT) in diabetic nephropathy (DN) in the 80's decade.- Dialytic treatment of diabetic patients with end -stage renal failure: 17 years of experience.- Analysis of a cohort of diabetics on dialysis: clinical and rehabilitation features related to dialysis age.- Relative risk of death in diabetic and non diabetic dialysis pts: a useful marker of a cohort features.- Chronic complications in diabetic hemodialyzed patients.- Impendance cardiographic evaluation of the central hemodynamic in diabetic patients treated with maintenance hemodialysis /HD.- A single-institution experience in 15-year dialysis treatment of diabetic patients.- IX. Transplantation.- Monoclonal antibodies OKT3 in resistant acute allograft rejections treatment.- Pancreas transplantation today: indications, techniques, and results in over 160 cases.- Determination of gamma Interferon and Neopterin serum levels for graft monitoring.- Xenogeneic transplantation: immunologic issues and future prospects.- The role of fine needle aspiration biopsy in the diagnosis of acute rejection in early and late post-transplant monitoring.- Temporary double-J stenting of the ureter following renal transplantation.- Acute phase response during monoclonal antibody treatment-relationship to antimonoclonal sensitization.- Protective effect of calcium-channel blockers on the cyclosporine (CyA)-related nephrotoxicity.- Lipid and Apoprotein profile in renal transplant recipients.- Thyroid function after renal transplantation.- Simultaneous pancreas-kidney transplantation: early detection of rejection by amylasuria determination.- Echo doppler sonography of the renal allograft acute rejection.- Renal hemodynamic effects of short-term therapy with low doses of cyclosporine A (CsA) in humans with intact kidney.- Modifications of plasma volume and ANF during long-term administration of cyclosporine.- Clinical implications of unexpected high glomerular filtration rate after renal transplantation.- Influence of HLA- class II on graft survival in patients with low cyclosporine doses.- Recurrence of focal glomerulosclerosis (FGS) following renal transplantation.- Author index.